Sanofi SA has appointed Jean-Paul Kress to its board, succeeding Gilles Schnepp who decided to leave the board at the end of 2024. Dr Kress was the chief executive officer of MorphoSys AG from 2019 until it was acquired by Novartis in 2024 and led the company’s global transformation developing and commercialising novel cancer medicines. With 30 years of executive experience in the pharmaceutical sector, Dr Kress will contribute to guiding Sanofi’s ongoing strategy. He received an MD from Faculté Necker-Enfants Malades and Master of Science in molecular and cellular pharmacology from Ecole Normale Supérieure (Ulm), both in Paris, France.
Sanofi announced the appointment on 19 December 2024.
Copyright 2025 Evernow Publishing Ltd.